Sun Pharmaceutical Industries Limited — Others, 04-02-2025: Action(s) taken or orders passed

Sun Pharmaceutical Industries Limited has received an order from the Additional Commissioner of Central GST & Central Excise, imposing a penalty of ₹1,602.29 crore related to a cross-charge of expenses. The company plans to appeal the order, asserting that there is no material impact on its financial or operational activities. This situation may generate cautious sentiment among investors due to the significant penalty; however, the company's intent to contest the order can also present a potential opportunity for future clarity and resolution.